An observational study was performed involving 95 children with vertically transmitted human immunodeficiency virus type 1 infection to assess the sustainability of undetectable viral loads (VLs) and increased CD4 + T lymphocyte percentages after 48 months of highly active antiretroviral therapy (HAART). The median time to achieve a 10% increase in the CD4 + T lymphocyte percentage was 11.01 months. The median time to achieve an undetectable VL was 6.4 months. At the end of the study, 64.2% of the children had achieved an undetectable VL. Of the patients with an initial VL of 13.6 log 10 copies/mL, 74.7% had a decrease in the VL of 1 log 10 copies/mL. By contrast, of the patients who presented with an initial VL of 14.6 log 10 copies/mL, 37.9% had a decrease of 12 log 10 copies/mL. Higher VL at baseline, antiretroviral therapy regimens received before HAART, and multiple drug switches while receiving antiretroviral therapy were all inversely associated with an undetectable VL. A CD4 + T lymphocyte percentage of 125% was directly associated with undetectable VL during the follow-up period. In conclusion, first-line HAART induces beneficial virological and immunological outcome responses in children.
lymphocyte percentage in many patients [3] [4] [5] , with good outcomes overall [6, 7] . However, most of these data are derived from clinical trials in which participants are selected and are well motivated to enroll, which means that the data do not always apply to infants [8] . On the other hand, once the results from ideal studies (i.e., clinical trials) have established the efficacy of HAART, additional cohort studies enable the analysis of the "real-life" effectiveness in a more heterogeneous population.
However, there are few observational studies on the effectiveness of HAART in the pediatric population that have monitored the 2 most relevant markers of progression to AIDS: percentage of CD4 + T lymphocytes and VL. Several studies have been conducted to evaluate the predictors of initial virological response to HAART [9] [10] [11] [12] [13] , but there are only few data on the "real-life" effects on HIV-infected children [14] . Indinavir and nevirapine 1 (1.1) 11.1
Nelfinavir and efavirenz 1 (1.1) 37.4
NOTE.
All regimens also included 2 nucleoside reverse-transcriptase inhibitors.
a Data are or mean. mean ‫ע‬ SEM For that reason, we performed an observational study involving a pediatric population to define the clinical impact of HAART on children. In particular, the present study aimed to assess decreases in the VL and increases in the CD4 + T lymphocyte percentage in children receiving HAART for 48 months. In addition, among those patients whose VL became undetectable, factors related to the subsequent reemergence of detectable virus were also investigated.
PATIENTS, MATERIALS, AND METHODS
Selection of patients and study design. This study is an assessment of the effect of HAART on a heterogeneous group of HIV-1-infected children being treated during the period of December 1996 through June 2001. Diagnoses were made by PCR detection of DNA and virus culture assays [15] . For this study, inclusion criteria were CD4 + T lymphocyte percentage quantification and detectable VL (1400 copies/mL) at study entry and у6 months of follow-up. From an initial cohort of 136 children who had vertically acquired HIV-1 infection, 12 children were excluded because we lacked data regarding their CD4 + T lymphocyte percentage or VL at study entry. An additional 29 children were excluded because they were !6 months of age and/or the duration of follow-up period while receiving first-line HAART was !6 months. Therefore, only 95 children fulfilled our inclusion criteria and were enrolled in the present observational study.
The clinical classification used and all drug regimens prescribed by the treating physician we in accordance with Centers for Disease Control and Prevention (CDC) guidelines [16, 17] . Children receiving antiretroviral treatment (ART) at baseline had previously been receiving monotherapy or combined therapy for у12 months. The response to therapy was evaluated every 3 months until the patients reached 24 months of age; it was then evaluated every 6 months. Evaluation was performed by serial measurements of CD4 + and CD8 + T lymphocyte percentages, determination of VL, and collection of clinical data, in accordance with published guidelines [17] . For each patient, possible changes in treatment regimens were made on the basis of clinical, immunological, and virological evolution and the aforementioned CDC guidelines and European guidelines for pediatric treatment.
T lymphocyte subsets in peripheral blood specimens were quantified by flow cytometry (FACScan; Becton-Dickinson Immunocytometry Systems) [15] . VL was measured in 200 mL of plasma using a quantitative assay (Amplicor Monitor; Roche Diagnostic Systems).
Exposure variables. During the entire follow-up period, all 95 HIV-1-infected children received first-line HAART (у2 nucleoside reverse-transcriptase inhibitors [NRTIs] plus у1 protease inhibitor [PI] and/or a nonnucleoside reversetranscriptase inhibitor [NNRTI] ). Patients were censored independently whenever they were switched to a second-line regimen. The antiretroviral drugs used are shown in table 1. As shown in table 1, patients receiving efavirenz had a shorter duration of treatment; this is because they entered this study later than the other patients. We analyzed the CD4 + T lymphocyte percentage and VL of HIV-1-infected children receiving first-line HAART. We stratified the children on the basis of baseline CD4 + T lymphocyte percentage, baseline VL, ART received, and changes made to antiretroviral drugs before HAART was administered.
We performed an additional substudy involving 74 children receiving second-line HAART from the 124 HIV-1-infected children. The reasons for their treatment changes included toxicity/intolerance (12 patients) and therapeutic failure (60 patients). Of the 60 patients with therapeutic failure, 13 had low adherence to HAART. The 12 children with toxicity/intolerance did not necessarily have virological and immunological failure, but they were treated as if they had presented with therapeutic failure, because they had also been previously exposed to HAART.
Outcome variables. We calculated the number of the 95 HIV-1-infected children receiving first-line HAART who had a decrease in the VL of 1 or 2 log 10 copies/mL, an undetectable VL (i.e., !400 copies/mL), and a rebound in the VL (i.e., an increase to 1500, 1000, and 4000 copies/mL) after achieving an undetectable VL. We determined the number of children who had increases (of 10%, 15%, and 20%) in the CD4 + T lymphocyte percentage. We also estimated the evolution of VL (i.e., a decrease in the VL of 1 log 10 copy/mL and achievement of an undetectable VL) in children receiving second-line HAART after treatment failure. Statistical analysis. Kaplan-Meier methods were used to determine the time to achievement of a virological and immunological response to HAART. The time was defined as the duration between baseline and the appearance of an increase in the CD4 + T lymphocyte percentage of 10%, 15%, or 20% (e.g., an increase in the CD4 + T lymphocyte percentage from 12% to 27% represents a 15% increase). Increases of 10%, 15%, and 20% increments in the CD4 + T lymphocyte percentage were only calculated in HIV-1-infected children receiving firstline HAART who presented with a CD4 + T lymphocyte percentage of !25% at baseline.
Similar methods were used to assess the time to an undetectable VL. We examined decreases in the VL of 1 or 2 log 10 copies/mL after the start of HAART. A decrease of 1 log 10 copies/ mL occurred if the baseline VL was 13.6 copies/mL. A decease of 2 log 10 copies/mL occurred if the baseline VL was 14.6 log 10 copies/mL. (These measurements actually refer to specific subjects in whom such a decrease in the VL could be detected [18] .) Age-adjusted Cox regression analyses were performed to assess the relative proportion (RP) of undetectable VLs.
RESULTS
Characteristics of the HIV-1-infected children. Ninety-five HIV-1-infected children receiving first-line HAART were studied throughout a follow-up period for as long as 48 months (the mean follow-up period for first-line HAART was 27.5 ‫ע‬ months). Each patient's follow-up period was measured 1.5 from the date that first-line HAART was started until a switch in antiretroviral drugs took place or the last available CD4 + T lymphocyte percentages and VL measurements were obtained. Clinical, immunological, and virological characteristics at baseline (i.e., study entry) are shown in table 2. By the end of the follow-up period, the CD4 + T lymphocyte percentage had improved significantly in all patients. A total of 62.1% of the children had a CD4 + T lymphocyte percentage of 125%. By contrast, only 10.2% of the children continued to have a CD4 + T lymphocyte percentage of !15%. The VL decreased in all children at the end of the study, and it was undetectable in 61% of the children.
The pre-HAART ART regimens administered to the 95 HIV-1-infected children are shown in table 3. Only 22 HIV-1-infected children were ART naive before they started receiving HAART, whereas the remaining 73 HIV-1-infected children had previously received ART (as monotherapy or combined therapy) before HAART for у12 months. Combined therapy consisted of ART with у2 nucleoside analogues. All drug switches involved nucleosides only. A total of 14 different combination ART regimens were administered before HAART.
During the entire follow-up period, HIV-1 infection pro- gressed to AIDS in only 3 children. All 3 children previously had clinical category B HIV infection and were given PIcontaining HAART regimens.
Kaplan-Meier analysis of CD4 + T lymphocyte percentage and VL. The Kaplan-Meier curves in figure 1A show the proportion of HIV-1-infected children with 10%, 15%, and 20% increases in the CD4 + T lymphocyte percentage at the end of the study. This was assessed only when the baseline CD4 + T lymphocyte percentage was !25% while receiving first-line HAART. By the end of study, 47 (71%) of 66 children had a 10% increase in the CD4 + T lymphocyte percentage, 36 (54.5%) had a 15% increase, and 22 (33.3%) had a 20% increase. Figure 1B shows the proportion of HIV-1-infected children who achieved an undetectable VL and who achieved a decrease in the VL of 1 or 2 log 10 copies/mL after starting HAART. By the end of study, 64.2% of the children had an undetectable VL. Of the children with an initial VL of 13.6 log 10 copies/mL, 74.7% had a decrease in the VL of 1 log 10 copies/mL, whereas 37.9% of children with an initial VL of 14.6 copies/mL had a decrease of 12 log 10 copies/mL.
The Kaplan-Meier graphs in figures 1C-E show the proportion of HIV-1-infected children with undetectable VL in relation to ART received, switches in antiretroviral drugs before HAART, and baseline VL. For children who were untreated before baseline, the median time to occurrence of an undetectable VL was 4.21 months, whereas, for children who were treated before study entry, the median time was 8.3 months ( figure 1C; ). HIV-1-infected children receiving mono-P p .06 therapy or combined therapy were equally likely to achieve an undetectable VL (data not shown). There were no differences between children with 1 drug switch and those with 2 drug switches. However, the children who had 12 switches in antiretroviral drugs before receiving HAART were the last to achieve undetectable VLs ( figure 1D ). Children with a VL of !30,000 copies/mL achieved control of their VL earlier in the follow-up period than did children with a VL of у30,000 copies/mL ( ) ( figure 1E ). P p .02 Cox regression analysis of undetectable VL in relation to baseline value. Table 4 shows the univariate and multivariate Cox regression analyses of the factors associated with the evolution of undetectable VL in patients receiving first-line HAART. Higher VL (130,000 copies/mL), 12 switches in antiretroviral drugs before receipt of HAART, and pre-HAART receipt of ART were inversely associated with achievement of an undetectable VL ( ). Moreover, baseline CD4 + T lym-P ! .05 phocyte percentages of 125% were directly associated with undetectable VL (table 4) . On multivariate analysis, a VL of 130,000 copies/mL and 12 antiretroviral drug switches before receipt of HAART was negatively associated with an undetectable VL. Also, a CD4 + T lymphocyte percentage of 125% was positively associated with an undetectable VL (table 4), as noted on univariate analysis.
Therapeutic failure. Sixty-one children had an undetectable VL and 34 did not achieve an undetectable VL. The children who achieved an undetectable VL presented with a lower baseline VL, and most of these children were ART naive before they received HAART or had made fewer antiretroviral drug switches before HAART (table 5) . Of the 95 children who achieved an undetectable VL, we selected 58 children who had у3 months of follow-up after reaching this end point. The characteristics of these 58 children are shown in table 5.
During the follow-up period, the 58 children with an undetectable VL while receiving first-line HAART, 28 (48.2%) had a rebound in the VL (i.e., an increase in the VL of 1 log 10 copies/mL or a VL of 14000 copies/mL; figure 2A ). In addition, 37 children (63.7%) who achieved an undetectable VL had a VL rebound of 11000 copies/mL, whereas 40 (68.9%) had a rebound of 1500 copies/mL (figure 2A). The median time to achieve an undetectable VL was 8.3 months (95% CI, 4.78-11.72; figure 2B ).
We performed a Cox regression analysis of the 58 HIV-1-infected children who an achieved undetectable VL to assess the factors associated with a rebound in the HIV level. Univariate analysis revealed that a lower CD8 + T lymphocyte percentage (RP, 0.97; 95% CI, 0.94-0.99) and a VL of 14 log 10 copies/mL (RP, 3.07; 95% CI, 1.04-8.99) were both directly associated with a rebound in the VL. We found that, among children with a VL of !4 log 10 copies/mL, only 50% had a VL rebound, whereas, among children with a VL of у4 log 10 copies/ mL, 76.2% had a VL rebound ( Baseline characteristics of HIV-1-infected children, by viral load (VL) during follow- analysis, only CD8 + T lymphocyte percentage was significant (RP, 0.96; 95% CI, 0.93-0.99). Figure 2C shows the percentage of patients who stopped receiving their initial HAART regimens.
Evolution of VL in patients receiving second-line HAART. Seventy-four children were recruited for a substudy of secondline HAART. The causes of treatment change were toxicity (12 patients) and therapeutic failure (60 patients). Thirteen of the 60 children who had therapeutic failure had poor adherence to treatment. We did not find any association between the cause of treatment change and the virological and immunological responses to second-line HAART.
The Kaplan-Meier graph in figure 3 depicts the proportion of HIV-1-infected children with an undetectable VL, among children with a 1-log 10 decrease in the VL after starting secondline HAART. The median time to achieve an undetectable VL was 17.26 months (95% CI, 10.5-24.0; figure 3) . A total of 53.3% of children had an undetectable VL. Among patients with a VL of 13.6 log 10 copies/mL when starting HAART, 72% had a decrease in the VL of 1 log 10 copies/mL. The most important factor related to undetectable VL while receiving second-line HAART was baseline VL before the second HAART regimen (RP, 0.51; 95% CI, 0.34-0.76). A VL of !10,000 copies/ mL had an RP of 2.82 (95% CI, 1.28-6.21).
DISCUSSION
When treating HIV-infected children who are starting HAART, it is crucial to detect signs associated with incomplete suppression of VL so that more-effective therapies can be implemented. This observational longitudinal study provides evidence from "real-life" data showing that first-line HAART attains sustained undetectable VLs in a significant proportion of children [12] . In our study, 64.2% of children achieved an undetectable VL after receiving HAART. This supports previously published results for adults [19] and children [20] . The median times to achieve a VL decrease in children receiving HAART are quite similar to those reported elsewhere for adults [18] . However, we found that the percentage of children with a decrease of 2 log 10 in the VL was greater than adults. Of interest, we found that a baseline CD4 + T lymphocyte percentage of 125% was a major predictor of achievement of an undetectable VL after receipt of first-line HAART, which is in agreement with recent reports [21] . This appears to argue in favor of earlier implementation of HAART, before the CD4 + T lymphocyte percentage decreases to !25%, despite the fact that those who start therapy with very low CD4 + T lymphocyte percentages may later attain normal percentages. Our results emphasize the relevance of regular CD4 + and CD8 + T lym- phocyte quantification to guide current decisions regarding the onset of therapy. HAART is most effective for the control of viral replication [22, 23] . Formerly used therapeutic regimens did not achieve proper VL control and, thus, promoted higher viral replication rates and the appearance of drug-resistant quasi species of HIV [24, 25] . Thus, HIV in infected children is likely to accumulate resistances before the children start receiving HAART, and those new quasi species facilitate quicker virological failure. Formerly used ARTs have been associated with virological failure both in adults [11, 26, 27] and in infants [28] . In our study, a significant number of HIV-1-infected children received antiretroviral drugs before HAART, with switches to other ART regimens. All of this could explain the high rate of VL rebound from undetectable VL present in these patients.
On the other hand, a sustained undetectable VL does not necessarily mean constant viral suppression. The VL was assessed every 3-6 months, and there could have been increases of 1400 copies/mL between measurements. Abrupt increases in the VL happen whenever the therapeutic regimen is reduced [29] [30] [31] . In some patients, an increase of VL may represent an overall less effective viral suppression leading to increases in drug-resistant HIV [32] [33] [34] . We found that the children receiving HAART who had higher VLs had a higher risk of virological failure.
A significant number of children received ART before HAART. After starting HAART, a dramatic decrease in the VL and an increase in the CD4 + T lymphocyte percentage ensued, to within the normal ranges for a child of that age [23] . Our study shows that prior ART is inversely associated with virological failure, as has been reported elsewhere for adults [11, 26] and infants [28] . This is noteworthy, given the clinical concern regarding the effectiveness of HAART as first-line therapy in children. We have found that HIV-1-infected children who have had 12 switches in the pre-HAART regimen had a higher risk of not achieving undetectable VL. The factors associated with therapeutic failure may be different in this subgroup of patients. For example, baseline VL and CD4 + and CD8 + T lymphocyte percentage may reflect the different effectiveness of ART in pretreated patients for reaching undetectable VL. We found that baseline VL was related to the likelihood of VL becoming undetectable after HAART, as well as to a VL rebound after reaching an undetectable VL, as has been reported elsewhere [11, 18, 19, 27, 35, 36] .
Sustained suppression of viral replication can be achieved in HIV-infected children receiving HAART [37] . However, it is difficult to achieve a sustained decreased VL to less than the detection limits of assays [7, 23] . Increases in CD4 + T lymphocyte percentage and clinical improvement take place concurrently [12, 38] , even in children with virological failure [39, 40] . However, a complete recovery of the immune system in patients receiving HAART does not always happen [41] . At the completion of this study, 62.1% children had CD4 + T lymphocyte percentages of 125%, compared with only 29.5% of children at baseline. This recovery in the CD4 + T lymphocyte percentage followed a decrease in the VL. Whether delayed initiation of HAART would compromise functional immune recovery in HIV-infected children justifies further research.
The influence of the choice of treatment regimen, baseline VL, and prior ART on HAART effectiveness has been reported elsewhere [11, 18, 35] . However, the factors related to the reemergence of detectable VL remain less clear. In this regard, CD8 + T lymphocyte percentage is a key prognostic marker. Our group has previously reported that the influence of HAART effectiveness is clearly dependent on baseline CD8 + T lymphocyte percentage [42] . A CD8 + T lymphocyte percentage of !25% may predict less effective virologic suppression and, therefore, may be used as a reliable marker to start HAART [42] . Our results reported the influence of HAART on the inhibition of viral replication. Higher CD8 + T lymphocyte percentages prevented a VL rebound. It is possible that, in cases involving inefficient control of HIV replication, earlier development of drug-resistant viruses may occur and eventually lead to virological failure [43] . Therefore, delaying HAART until the CD8 + T lymphocyte percentage decreases to lower levels may have a greater long-term effect on the ability to maintain VL suppression or an undetectable VL, raising questions about the competence of their reconstituted immune function. Strong evidence supports the hypothesis that cytotoxic T lymphocytes have a role in suppressing HIV-1 infection [44, 45] . CD8 + T lymphocyte count has been reported to be a prognostic marker in HIV-infected children [46] , and a low CD8 + T lymphocyte count may involve a low number of HIV-1-specific cytotoxic T lymphocytes. This may explain the relationship between CD8 + T lymphocyte count and worse virological outcome, and it may strengthen the importance of this marker in defining the response to HAART. By contrast, we have found that a higher baseline CD8 + T lymphocyte percentage protected against a VL rebound after achievement of an undetectable VL. On the other hand, a higher baseline VL is also associated with VL rebound.
Response to therapy has been shown to be highly dependent on the patient's adherence to therapy [47, 48] . Adherence to treatment is extremely important and may have a significant, unaccounted-for effect on the interpretation of our results. The level of adherence varies among patients, ranging from poor to strong. However, in this study, we did not categorize patients according to their degree of adherence to treatment. Our results demonstrate that poor adherence to HAART results in suboptimal drug levels, which strongly contribute to virological failure. A high proportion of children stopped first-line HAART, with indinavir being the drug most often discontinued. No further data are available on this issue. This could explain our observations and yet be a limitation to our analysis.
It is also important to address the growing concern that toxicities associated with long-term treatment may significantly outweigh the risks of the early initiation of treatment in clinically stable children with a relatively preserved immune status. We advocate early initiation of treatment to secure an adequate and sustained response, although the risks must be firmly considered. Possible side effects include metabolic disturbances, such as lipodystrophy, lactic acidosis, and increased triglyceride levels [49, 50] . Guidelines for adults and children have recently liberalized treatment recommendations [51] . We have described the use of second-line HAART to determine the median of time to virological response. This response was lower during secondline HAART: only 53.3% HIV-1-infected children achieved undetectable VL, and it took 3 times longer to be achieved. Lower baseline VL at the time of initiation of second-line HAART is associated with undetectable VL.
In conclusion, first-line HAART induces beneficial effects in terms of virological and immunological outcome responses, especially when given to treatment-naive children. This study may be of great importance to persons making treatment decisions regarding initiation of HAART for antiretroviral-naive children.
